Screener / SEC EDGAR /CIK 0001356576 /10-K filed Mar 2, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care · Pharmaceuticals

Supernus, Inc. SUPN

Compare with peers Embed
SEC comment letters, last 20 years

3 reviews of SUPN's filings by SEC staff

UPLOAD and CORRESP
Reviews 3 latest letter Jul 17, 2019
Questions asked 11 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 11 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 2 of 3 closing letter

Half the closed reviews took 77 days or less from the first letter to the closing letter.

Form 10-Q

2019-07-17 to 2019-07-31 · 3 questions · 1 letter from the SEC, 1 from the company
No closing letter
Results discussion (MD&A)
Results of Operations · Comparison of the three month periods ended March 31, 2019 and 2018 Net Product Sales, page 28
SEC asked (1)
Regarding sales discounts, please tell us why the provision for sales in the current year as a percentage of gross product sales during the quarter and the allowance as a percentage of gross accounts receivable as of the end of the quarter both decreased in 2019 as compared to the 2018.
SUPN answered
The current year provision for sales discounts and gross product sales for the quarters ended March 31, 2019 and March 31, 2018 were as follows:

($ in millions)

Quarter Ended

March 31, 2019

March 31, 2018

Gross product sales

$

159.0

155.9

Current year provision — sales discounts

11.2

12.2

As a percentage of gross product sales

7.1

%

7.8

If the relationship between gross product sales and the current year provision for sales discounts for the quarter ended March 31, 2019 was consistent with the quarter ended March 31, 2018, the implied current year provision for sales discounts
Rest of the answer

would have been approximately $12.4M for the quarter ended March 31, 2019, or $1.2M higher than the actual reported provision of $11.2M.

As described in the background section above, the [***] to [***] from [***] was approximately $[***] in 2019, as compared to 2018. This [***] resulted in a year-over-year [***] in sales discounts, and is a direct consequence of the inventory build-up by the wholesalers/distributors [***] to the [***] for Supernus’ products. This [***] applies to the on-hand inventory as of January 1.

In addition, the $[***] represents [***]% of gross product sales, explaining the 0.7% difference between the 7.1% and 7.8% referenced in the table above.

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-003

Question 1B.

The allowance for sales discounts and gross accounts receivable balances as of March 31, 2019 and March 31, 2018 were as follows:

Gross accounts receivable

87.8

77.2

Allowance for sales discounts

9.4

As a percentage of gross accounts receivable

8.9

12.1

If the relationship between gross accounts receivable and the allowance for sales discounts as of March 31, 2019 was consistent with March 31, 2018, the implied allowance for sales discounts would have been approximately $10.6M as of March 31, 2019, or $2.8M higher than the actual reported allowance for sales discounts of $7.8M.

Of the aggregate change, approximately $[***], or [***]% of gross accounts receivable, is attributable to a change in timing of service fees paid to wholesalers/distributors in 2018 versus 2019. Specifically, in 2018, the service fees earned by two of our wholesalers/distributors in January were paid in April. In 2019, service fees earned by these wholesalers/distributors in January were paid in March.

In addition to this timing difference, and as described previously, the $[***] year-over-year [***] in [***] to [***] from [***] in 2019 [***] sales discounts in 2019, representing [***]% of gross accounts receivable. This [***] is a direct consequence of the inventory build-up by wholesalers/distributors [***] to the [***] for Supernus’ products.

Combining the timing effect ([***]% of gross accounts receivable) with the [***] effect ([***]% of gross accounts receivable) results in a combined effect of [***]%, which explains the difference between the 8.9% and 12.1% referenced in the table above.

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

Read in the reply
In its next report

First report after the company's reply of Jul 31, 2019: 10-Q filed Aug 9, 2019 ↗, against the 10-Q filed May 10, 2019 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Results of Operations · Comparison of the three month periods ended March 31, 2019 and 2018 Net Product Sales, page 28
SEC asked (2)
Regarding the accrued liability for rebates, please tell us why it was $18.9 million higher at December 31, 2018 than at March 31, 2019.
SUPN answered
The accrued liability for rebates decreased $18.9M as detailed below:

December 31, 2018

85.0

66.1

Decrease

18.9

This decrease in the accrued liability for rebates is primarily a result of timing differences in the settlement of outstanding amounts. Rebates are paid when due, which is generally based on when the invoices are received.
Rest of the answer

Approximately $[***] of rebate payments in conjunction with Medicaid were settled in January 2019 that historically would have been settled in December 2018.

The remainder of the decrease, $[***], is primarily due to lower gross product sales in the first quarter of 2019 as compared to the fourth quarter of 2018. Gross product sales decreased by approximately $[***] from fourth quarter of 2018 to first quarter of 2019. This reduction is the result of the reversal of the inventory build-up by wholesalers/distributors that occurred at the end of 2018 coupled with lower prescription volume in the first quarter of 2019. This reduction in gross sales directly caused a reduction in rebate accruals as of March 31, 2019 as compared to December 31, 2018.

Read in the reply
In its next report

First report after the company's reply of Jul 31, 2019: 10-Q filed Aug 9, 2019 ↗, against the 10-Q filed May 10, 2019 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Results of Operations · Comparison of the three month periods ended March 31, 2019 and 2018 Net Product Sales, page 28
SEC asked (3)
Please consider whether revised disclosure is necessary in response to the above comments and, if so, provide us proposed disclosure to be included in your June 30, 2019 Form 10-Q.
SUPN answered
Management has considered the questions and answers above as we developed our MD&A disclosures for the second quarter Form 10-Q filing. Management has and will continue to monitor the fluctuations and trends within our sales deductions to ensure we are disclosing all material items. Although much of what follows has been disclosed in previous filings, we propose the following disclosures in the Management’s Discussion and Analysis Section of the second quarter Form 10-Q filing:

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange
Rest of the answer

Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-005

Results of Operations

Sales deductions and related accruals

The Company records accrued rebates and accrued product returns in our balance sheet under Accrued product returns and rebates as current liabilities and records sales discounts as a valuation allowance against Accounts receivable. The outstanding amounts of accrued product returns, rebates and allowance for sales discounts as of the respective balance sheet dates are generally affected by the changes in level of gross sales, provision for net product sales deductions and timing of payments/credits.

The following table provides a summary of activities with respect to sales deductions and related accruals for the six months ended June 30, 2019 and 2018, respectively, in thousands of dollars:

Accrued Liabilities

Rebates

Product

Returns

Allowance for

Sales Discounts

Total

Balance at December 31, 2018

85,003

22,060

11,548

118,611

Provision

Provision for sales in current year

139,376

4,068

27,394

170,838

Adjustments relating to prior year sales

(888

)

(730

(43

(1,661

Total provision

138,488

3,338

27,351

169,177

Less: Actual payments/credits

(149,129

(3,826

(26,940

(179,895

Balance at June 30, 2019

74,362

21,572

11,959

107,893

Balance at December 31, 2017

49,460

18,883

8,892

77,235

109,300

4,366

26,885

140,551

(1,744

(81

(3

(1,828

107,556

4,285

26,882

138,723

(105,634

(4,506

(26,550

(136,690

Balance at June 30, 2018

51,382

18,662

9,224

79,268

Overall, the total provision for sales deductions on gross product sales increased by $30.5 million, or 22%, from $138.7 million to $169.2 million, for the six months ended June 30, 2018 and 2019, respectively. Virtually all of this increase is attributable to the year over year increase in the provision for product rebates, of $30.9 million, or 29%.

Year over year increase in the provision for product rebates is primarily attributable to greater utilization of our patient co-pay program. Expansion of this program is attributable, in part, to the continued growth in high deductible health care plans. Growth

SUPN-006 in prescriptions, and the impact of the 8% price increase taken in January, contributed to the secular increase in product rebates.

Partially offsetting these factors is the effect of the aforementioned reduction in inventory levels at the wholesaler, distributor and pharmacy levels, which effectively reduced rebates.

The decrease in the provision for product returns, approximately $0.9 million, is due primarily to favorable actual returns experience.

Provision for allowance for sales discounts marginally increased by $0.5 million, from $26.9 million to $27.4 million for the six months ended June 30, 2018 and 2019, respectively. The increase is directly attributable to the prescription volume.

Adjustments related to prior year sales due to changes in our estimates had a de minimis impact on net product sales for the three and six month periods ended June 30, 2019 and 2018.

Read in the reply
In its next report

First report after the company's reply of Jul 31, 2019: 10-Q filed Aug 9, 2019 ↗, against the 10-Q filed May 10, 2019 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Form 10-K for the Fiscal Year Ended December 31, 2017

2018-09-21 to 2018-12-07 · 4 questions · 2 letters from the SEC, 2 from the company
Review closed 2018-12-07
RevenueCritical estimatesInventoryIncome taxesReserves and insurance
Critical Account Policies and Use of Estimates · Revenue Recognition, page 64
SEC asked (1)
You identify product revenue recognition as a critical accounting estimate. Given the magnitude of your net product sales and your gross-to-net adjustments as previously conveyed in your quarterly earnings conference calls, please address the following: • Provide us a roll forward of the accrual of each gross-to-net adjustment type (whether reflected as an allowance against accounts receivable or a liability) that
Rest of the question

depicts the following for each annual period from January 1, 2016 to December 31, 2017 and for the six-month period from January 1, 2018 to June 30, 3018: o Beginning balance; o Current provision related to sales made in current period; o Current provision related to sales made in prior periods; o Actual returns or credits in current period related to sales made in current period; o Actual returns or credits in current period related to sales made in prior periods; and o Ending balance. • Tell us the amount of and reason for significant fluctuations in the provision from period to period for each type of gross-to-net adjustment, and the amount and reason that changes in your estimates of these items had on your revenues and operations. • Tell us why the balance of your accrued sales deductions is greater than your net accounts receivable at December 31, 2016 and 2017.

SUPN answered
The Company acknowledges the Staff’s comment regarding our net product sales and gross-to-net adjustments as critical accounting estimates. Many of our gross-to-net adjustments are typical within our industry and with our peers. Our products are distributed through a third party fulfillment center. We recognize revenue when the product is shipped from this center to our customers, who are wholesalers that stock product to fulfill orders from retail pharmacy chains of varying size and buying power.
Rest of the answer

For competitive purposes, the Company does not disclose or distribute sensitive information with respect to specific gross-to-net provisions on individual products.

Accrued sales deductions liability on the financial statements is comprised of accrued rebates and allowances and allowance for product returns (refer to Appendix I for reconciliation to the financial statements). Accrued rebates and allowances primarily include: rebates due to managed care providers under specific contracts; rebates due to various organizations under government programs (e.g., Medicaid, Medicare, Chargebacks, etc.); and amounts due under patient co-pay assistance programs. We estimate our liability for rebates and allowances from an analysis of historical levels of deductions specific to each product, as well as contractual terms with our customers. In addition, we consider the impact of actual and anticipated changes in product price,

SUPN-002 sales trends and changes in managed care coverage and co-pay assistance programs. Although the contractual terms, price and the total shipments to wholesalers are known during the reporting period, we project the ultimate disposition of the sale (i.e., future utilization rates of cash payors, managed care, Medicaid or other contracted organizations). This projection is based on historical trends adjusted for anticipated changes based on specific contractual terms of new agreements with customers.

Our allowance for product returns is based primarily on actual returns data generated by our two commercial products and industry returns experience for similar products (i.e., ambient temperature storage of oral formulations). Our products are still in the process of maturing in the marketplace, and as we gain additional experience with our products, we adjust our allowance for product returns as applied to both sales consummated in the current period as well as sales made in prior periods.

Our allowance for product returns is also affected by price increases. Our products have expiry dating of 3 – 4 years, and our returned goods policy allows for product to be returned six months prior to and up to 12 months post expiry date. Our policy permits product returns to be processed at current wholesaler price rather than historical purchase price. Any price increase(s) taken during the current period therefore affects our provision for product returns for both sales made in the current period as well as sales made in prior periods.

Allowance for sales discounts are recorded against accounts receivable and include: discounts due in connection with contractual arrangements for distributor allowances and service fees with wholesalers and prompt pay discounts.

Accrued Rebates and Allowances

Trokendi XR:

(in thousands)

Beginning Balance

Current provision related to sales made in current period made in prior periods

Actual returns or credits in current period related to sales made in current period prior periods

Ending

Balance

December 31, 2016

[***]

December 31, 2017

June 30, 2017

June 30, 2018

Period over period comparison

12/31/17 vs 12/31/16

Total current provision – 2016

Total current provision – 2017

[***] in current provision - $

[***] in current provision - %

6/30/18 vs 6/30/17

Total current provision – 2018

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-003

December 31, 2017 versus December 31, 2016

As shown in the table above, the aggregate provision for rebates and allowances for Trokendi XR [***] from [***] in 2016 to [***] in 2017. The aggregate year-over-year [***] in the provision for rebates and allowances was therefore [***] or [***]. This year-over-year [***] can be approximately disaggregated into the following causal factors:

· Prescription volume, as reported by IQVIA, increased by approximately 41% from 2016 through 2017, causing provision for rebates and allowances to increase by the same percentage amount.

· Price increases in excess of the Consumer Price Index (CPI) resulted in higher Medicaid rebates for patients covered under this program. The aggregate impact on the provision for rebates and allowances was a year-over-year increase of [***].

· For patients covered under private insurance, per patient rebates and allowances to commercial plans resulted in an aggregate year-over-year [***] in the provision for rebates and allowances of [***]. In addition, the Company [***] its per patient co-payment support for patients covered under private insurance. This [***] coverage resulted in an aggregate year-over-year [***] in the provision for rebates and allowances of approximately [***].

1H 2018 versus 1H 2017

As shown in the table above, the aggregate provision for rebates and allowances for Trokendi XR [***] from [***] in the first half of 2017 to [***] in the first half of 2018. The aggregate period to period [***] in the provision for rebates and allowances was therefore [***], or [***], which can be approximately disaggregated into the following causal factors:

· Prescription volume, as reported by IQVIA, increased by approximately 51% from first half 2017 through first half 2018, causing the provision for rebates and allowances to increase in the same percentage amount.

· Price increases in excess of the Consumer Price Index (CPI) resulted in higher Medicaid rebates and allowances for patients covered under this program. The aggregate impact on the provision for rebates and allowances was a year-over-year increase of [***].

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-004

· For patients covered under private insurance, the contractual per patient rebates and allowances to commercial plans resulted in an aggregate year-over-year [***] in the provision for rebates and allowances of [***]. In addition, the Company [***] its per patient co-payment support for patients covered under private insurance. This [***] coverage resulted in an aggregate year-over-year [***] in the provision for rebates and allowances of approximately [***].

Oxtellar XR:

As shown in the table above, the aggregate provision for rebates and allowances for Oxtellar XR [***] from [***] in 2016 to [***] in 2017. The aggregate year-over-year [***] in the provision for rebates and allowances was therefore [***], or [***]. This year-over-year [***] can be approximately disaggregated into the following causal factors:

· Prescription volume, as reported by IQVIA, increased by approximately 12% from 2016 through 2017, causing the provision for rebates and allowances to increase in the same percentage amount.

· Price increases in excess of the Consumer Price Index (CPI) resulted in higher Medicaid rebates and allowances for patients covered under this program. The aggregate impact on the provision for rebates and allowances was a year-over-year increase of [***].

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-005

· For patients covered under private insurance, rebates and allowances to commercial plan providers and [***] patient co-payment support resulted in a total year-over-year [***] of [***] in the provision for rebates and allowances.

As shown in the table above, the aggregate provision for rebates and allowances for Oxtellar XR [***] from [***] in the first half 2017 to [***] in first half 2018. The aggregate period to period [***] in provision for rebates and allowances was therefore [***], or [***]. This period to period [***] can be approximately disaggregated into the following causal factors:

· Prescription volume, as reported by IQVIA, increased by approximately 10% from period to period, causing the provision for rebates and allowances to increase in the same amount.

· Price increases in excess of the Consumer Price Index (CPI) resulted in higher Medicaid rebates and allowances for patients covered under this program. The aggregate impact on the provision for rebates and allowances was a [***] increase.

· For patients covered under private insurance, contractual rebates and allowances to commercial plan providers and [***] patient co-payment support resulted in an aggregate [***] of [***] in the provision for rebates and allowances.

Product Returns

Our allowance for product returns is based primarily on actual returns data generated by our two commercial products and industry returns experience for similar products (i.e., ambient temperature storage of oral formulations). Our products are still in the process of maturing in the marketplace, and as we gain additional experience with our products, we adjust our allowance for product returns as applied to both sales consummated in the current period as well as sales made in prior periods.

Our allowance for product returns is also affected by price increases. Our products have expiry dating of 3 – 4 years, and our returned goods policy allows for product to be returned six months prior to and up to 12 months post expiry date. Our policy permits product returns to be processed at current wholesaler price rather than historical purchase price. Any price increase(s) taken during the current period therefore affects

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-006 our provision for product returns for both sales made in the current period as well as sales made in prior periods.

Trokendi XR

During calendar year 2016, we experienced [***] for Trokendi XR. This experience was the primary driver affecting the [***] in the provision related to sales in the current period [***] as well as the provision related to sales made in prior periods [***]. To a lesser extent, year-over-year [***] in price and volume also contributed to the [***].

In the next year, 2017, product returns [***], resulting in [***] provisions for sales made in the current period [***] as well as sales made in prior periods [***]. As a result, the [***] for product returns for Trokendi XR [***] by [***], from [***] in 2016 to [***] in 2017.

As shown in the table above, the aggregate period to period change in the product returns provision for Trokendi XR was an [***] of [***], or [***]. In this timeframe, [***] returns [***] our expectations. The period to period [***] was therefore driven primarily by [***] and [***].

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-007

During calendar year 2016, we experienced [***] for Oxtellar XR. This experience was the primary driver affecting the [***] in the provision related to sales in the current period [***] as well as the provision related to sales made in prior periods [***]. To a lesser extent, year-over-year [***] in price and volume also contributed to the [***].

In the next year, 2017, product returns [***] to be the primary driver affecting the period to period [***] in the provision for sales in the current year [***] and sales made in prior years [***]. As a result, the aggregate allowance for product returns for Oxtellar XR [***] by [***] or [***], from [***] in 2016 to [***] in 2017.

As shown in the table above, the aggregate product returns provision for Oxtellar XR [***] by [***], or [***] period to period. In this timeframe, [***] returns [***] our expectations. The period to period [***] was therefore driven primarily by [***] and [***].

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-008

Allowance for Sales Discounts:

As shown in the table above, the aggregate provision for cash discounts [***] from [***] in 2016 to [***] in 2017. The aggregate year-over-year [***] in the provision for sales discounts was therefore [***], or [***]. This year-over-year [***] can be disaggregated into the following causal factors:

· Prescription volume, as reported by IQVIA, increased by approximately [***] and [***] from 2016 through 2017 for Oxtellar XR and Trokendi XR, respectively. This gave rise to a composite increase of approximately [***] in year-over-year sales discounts.

· Price increases taken during 2017 increased year-over-year sales discounts by approximately [***].

As shown in the table above, the aggregate provision for sales discounts [***] from [***] in the first half of 2017 to [***] in the first half of 2018. The aggregate period to period [***] in the provision for sales discounts was therefore [***], or [***]. This period to period [***] can be disaggregated into the following causal factors:

· Prescription volume, as reported by IQVIA, increased by approximately [***] and [***] when comparing the first half of 2017 to the first half of 2018 for Oxtellar XR

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-009 and Trokendi XR, respectively. This gave rise to a composite increase of approximately [***] in period to period sales discounts.

· Price increases taken during 2017 and 2018 increased period to period sales discounts by approximately [***].

Accrued Sales Deductions Versus Accounts Receivable

As described below, the settlement time for accrued sales deductions is substantially greater than the collection lag time for accounts receivable. This phenomena resulted in the Company’s accrued sales deduction balance being greater than the net accounts receivables balance as of December 31, 2016 and 2017.

Accounts receivable represents amounts outstanding from customers less an allowance for doubtful accounts and discounts.

The recorded allowance for sales discount as of June 30, 2018, December 31, 2017 and December 31, 2016 was approximately $9.3 million, $8.9 million and $5.6 million, respectively. The Company records a receivable and the corresponding estimate for allowance of discount at time of sale. Both the outstanding receivable and the allowance for discount is relieved at time of collection. The Company’s average days sales outstanding, a measure of time it takes to collect our net accounts receivable, has typically ranged from 62 days to 72 days over the past three years.

Accrued sales deductions liability represent amounts owed for rebates and allowances, patient co-pay assistance and product returns. The Company records the estimated accrued sales deductions at the time of sale. There is a significant time lag between the time of sale and settlement of these liabilities, in particular for Medicaid rebates and allowances and product returns.

Medicaid rebates and allowances are paid to individual states after the states submit their invoices, which generally occurs six to nine months after the date of sale. Settlement of Medicaid rebates and allowances generally occurs one to two months after the receipt of invoice, or seven to eleven months after sale.

Our product has between 36 months and 48 months dating from time of packaging to expiration. The Company accepts product returns six months prior to and up to 12 months after its expiry date. Due to the lengthy shelf life of our products and the terms of our return policy, there is a time lag of as much as four to five years between the date we determine the estimated allowance for product returns (i.e., date of sale) and when expired product is ultimately returned.

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

Read in the reply
In its next report

First report after the company's reply of Oct 5, 2018: 10-Q filed Nov 9, 2018 ↗, against the 10-Q filed Aug 9, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Summary of Significant Accounting Policies · Inventories, page 86
SEC asked (2)
Please confirm for us whether you reflect your inventories at the lower of cost or net realizable value under ASC 330-10-35-1B as added by ASU 2015-11 instead of the disclosed lower of cost or market. If so, represent to us that you will modify your policy disclosures in future periodic reports accordingly. Otherwise, please advise.
Rest of the question

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

SUPN answered
The Company acknowledges the Staff’s comment and confirms that inventories are reflected at the lower of cost or net realizable value under ASC 330-10-35-1B as added by ASU 2015-11. The reference to “lower of cost market” in the Form 10-K was erroneously carried over from prior periods. The Company respectfully advises the Staff that it will update its policy disclosure in future periodic reports accordingly.
Read in the reply
Critical Accounting Policies and Use of Estimates · Revenue Recognition, page 64
SEC asked (1)
It appears from your response to prior comment 1 that your gross-to-net adjustments recorded in 2016 related to sales of prior years was significant to your operating earnings and earnings before income taxes in 2016.
Rest of the question

To the extent that re-estimates of prior year gross-to-net variable consideration is significant in future periods, please represent to us that you will disclose herein the impact on your product sales and operating results and include in your financial statements the disclosure required by ASC 606-10-50-12A.

SUPN answered
The Company acknowledges the Staff’s comment regarding the required disclosures under ASC 606-10-50-12A. The Company adopted ASC 606 at January 1, 2018, the effective date of the standard. Quarterly, the Company evaluates the adjustments of prior year gross-to-net variable considerations and to the extent that these adjustments are determined to be significant, the Company will disclose any such adjustments in its current financial statements.
Rest of the answer

The Company notes that we have included a disclosure in the footnotes section of the Form 10-Q reports filed in 2018 specifically disclosing the results of our evaluation that revenue recognized from performance obligations related to prior periods were not material. See references below:

· Page 11 of report on Form 10-Q for the Quarterly Period Ended March 31, 2018

· Page 12 of report on Form 10-Q for the Quarterly Period Ended June 30, 2018

· Page 12 of report on Form 10-Q for the Quarterly Period Ended September 30, 2018

The Company confirms that it will continue to disclose the impact of changes to prior year gross-to-net variable considerations, to the extent these are significant, and include the disclosures in the financial statements as required by ASC 606-10-50-12A.

Read in the reply
In its next report

First report after the company's reply of Nov 16, 2018: 10-K filed Mar 1, 2019 ↗, against the 10-K filed Mar 1, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Critical Accounting Policies and Use of Estimates · Revenue Recognition, page 64
SEC asked (2)
It appears from your response to prior comment 1 that your gross-to-net adjustment for sales returns of Oxtellar XR recorded in 2016 related to prior period sales was significant to your net product sales for Oxtellar XR in 2016 and to your estimated reserve balance at December 31, 2015.
Rest of the question

Given the magnitude of this adjustment recorded in 2016, please tell us how you were able to make reasonable estimates of product returns in order to recognize product sales of Oxtellar XR revenue upon product shipment under ASC 60515-25-1f applicable at the time.

SUPN answered
The Company advises the staff that we believe that recognition of revenue for our Oxtellar XR product at the time of shipment to wholesalers / distributors meets the condition for revenue recognition under ASC 605-15-25-1f.

The Company believes we have consistently applied a reasonable and supportable basis for determining our estimate for future product returns and that the magnitude of the adjustment in 2016 was not material to our overall financial results.

EXPIRED PRODUCT RETURNS POLICY:

Oxtellar XR is a medication for treatment of epilepsy.
Rest of the answer

Epilepsy is a chronic condition, with patients maintaining once daily dosing until or unless being switched to an alternative therapy. Failure to maintain daily dosing greatly increases the likelihood of seizure(s).

Consistent with the pharmaceutical industry practice, our returned goods policy allows for undamaged and unused product to be returned six months prior to and 12 months post expiry date of that lot. Prior to expiry, neither wholesalers nor pharmacies can

SUPN-002 return undamaged or unused product. At launch in 2013, Oxtellar XR had three year dating. Product dating has subsequently been increased to four years. Due to the expiration dating of Oxtellar XR, wholesalers and distributors typically have 18 months to 42 months to sell product before it is eligible for return.

The Company’s product returns policy generally permits returns to be processed at current wholesaler price, rather than at historical purchase price. Consequently, any price increase(s) taken during the current period increases our provision for product returns, for both sales made in the current period as well as sales made in prior periods.

RETURNS METHODOLOGY AND PROCESS FOR RETURNS PROVISIONING:

Our methodology for establishing the allowance for product returns is based on two factors. First, actual returns data generated by our commercial products. Second, industry returns experience for similar products; i.e., ambient temperature storage of oral formulations. Our methodology is further informed by prescription data and inventory held in the supply chain. The Company calculates the estimated provision for returns quarterly, by lot and for each individual product. Our estimates have been refined as new returns information is gained.

Regarding actual returns data, our methodology calculates, for each lot, the number of units returned as a percentage of the total number of units shipped. On a quarterly basis, we compute the actual return rate for that lot, as of quarter end, and project the return rate for that lot through 12 months post expiry; i.e., through to its ultimate return date. As we generate additional actual returns experience, we increasingly rely on the actual data set of information, and consequently rely diminishingly on industry experience.

For lots which have not yet reached expiry, the Company uses both actual returns data generated in preceding Oxtellar XR lots, as well as industry returns experience for products similar to Oxtellar XR; e.g., ambient storage; oral formulation; comparable shelf life, and same dosage form. Based on information provided by the three major pharmaceutical product wholesalers / distributors (i.e., McKesson Corporation, Cardinal Health, Inc. and Amerisource Bergen Corporation, collectively “the Three Major Wholesalers / Distributors”), we ascertained that the return rate at ‘steady state’ (i.e., 5+ years post launch) for a product such as Oxtellar XR is expected to range from [***] to [***] of each lot.

In January 2014, product dating was extended for Oxtellar XR to four years. Extended dating affords pharmacists greater opportunity to fill prescriptions from stock on hand and thereby reduce the exposure for returns because there is a longer period during which pharmacies can sell the product.

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-003

Oxtellar XR is still in the process of maturing in the marketplace. Consequently, as we gain additional returns experience, we adjust our allowance for product returns as applied to both sales consummated in the current period as well as sales consummated in prior periods.

ASC 605 FACTORS (ASC 605-15-25-3A THROUGH 3D) AND SAB TOPIC 13(A)(4)(B).

The Company reviewed ASC 605 factors as well as SAB Topic 13 in assessing factors which would allow determination of product returns.

· Susceptibility of product to significant external factors, such as technological obsolescence or changes in demand.(1)

Oxtellar XR is a branded pharmaceutical product and has multiple Orange Book listed patents that do not expire until 2027, which we believe should inhibit generic entry. To our knowledge, there are no products which would render Oxtellar XR technologically obsolete, either in the market or under development. We believe we have significant visibility on new potential market entrants.

Based on our assessment, we believe this factor is not present and therefore does not impede our ability to make reasonable estimates of product returns.

· Relatively long periods in which a particular product may be returned.

As explained in our returns policy, we allow product to be returned 6 months prior to and up to 12 months post expiration. These are standard terms within the pharmaceutical industry and therefore are customary and not atypically long.

Based on our assessment, we believe this factor is not present and therefore does not impede our ability to make reasonable estimates of product returns.

· Absence of historical experience with similar type of sales of similar products, or inability to apply such experience because of changing circumstances, for example changes in selling enterprise’s marketing policies or relationships with customers.

For lots which have not yet reached expiry, the Company uses both actual returns data generated in preceding Oxtellar XR lots, as well as industry returns experience for products similar to Oxtellar XR; e.g., ambient storage; oral formulation; comparable shelf life, and dosage form. Based on information provided by the three major pharmaceutical product wholesalers / distributors, we ascertained that the

(1) We have considered similar additional factors under SAB Topic 13(A)(4)(b) pertaining to expected introductions of new products or competitor’s products that may result in the technological obsolescence and for same reason as indicated in our response above, determined these factors are not present and therefore do not impact our ability to estimate returns.

SUPN-004 return rate at ‘steady state’ (i.e., 5+ years post launch) for a product such as Oxtellar XR is expected to range from [***] to [***] of each lot.

There are numerous other branded extended release anti-epileptic products within the industry. Our product is not unique in that regard.(2)

Although the Company’s historical return experience in 2016 for Oxtellar XR was limited, there was available industry data for products similar to Oxtellar XR to support the estimated return rate, as discussed. Therefore, we believe this factor does not impede our ability to make reasonable estimates of product returns.

· Absence of large volume of relatively homogenous transactions:

Oxtellar XR is a drug in oral dosage form (i.e., tablet) which is packaged with a regulatory approved NDC number for each dosage form and sold in large volumes of homogenous transactions.

Based on our assessment, we believe this factor is not present and therefore does not impede our ability to make reasonable estimates of product returns.

· Lack of visibility into or the inability to determine or observe the levels of inventory in a distribution channel and the current level of sales to end user:

Since launch, we observed stable growth in patient usage of the product, stable product ordering patterns and stable weeks of coverage at our wholesalers / distributors. We have a high degree of visibility with regard to inventory levels and throughput of wholesalers/distributors.

We regularly monitor channel quantities by reviewing the weekly supply reports from the Three Major Wholesalers / Distributors, which represents 96% of sales in 2015 and 2016, and by purchasing third party prescription data to monitor inventory and throughput at the pharmacy level.

Based on this monitoring, we estimate product held at distributors and on pharmacy shelves in 2015 and 2016. Because inventory held by wholesalers consists of relatively recently manufactured product, and therefore has several years of remaining dating, the risk of expired product returns from distributors is minimal. Based upon our historical review of the morgue reports (i.e., nonsalable inventory) from the wholesalers / distributors, we observed little/no inventory being held for return.

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

(2) We have considered the newness of the product factor under Topic 13(A)(4)(b) and for same reason as indicated in our response above, determined this factor is not present and therefore does not impact our ability to estimate returns.

SUPN-005

Based on our assessment, we believe this factor is not present and therefore does not impede our ability to make reasonable estimates of product returns.

· Significant increases in or excess levels of inventory in a distribution channel (aka channel stuffing):

We regularly monitor channel quantities by reviewing the weekly supply reports from the Three Major Wholesalers / Distributors, which represents 96% of sales in 2015 and 2016, and by purchasing third party prescription data to monitor inventory and throughput at the pharmacy level. Based on this information, we have not seen any significant increases or excess levels of inventory at any stage of the distribution channel.

We have not sold short-dated product nor engaged in pricing or promotional activities which could result in channel stuffing.

Based on our assessment, we believe this factor is not present and therefore does not impede our ability to make reasonable estimates of product returns.

· The significance of a particular distributor to the registrant’s (or a reporting segment’s) business, sales and marketing:

We sell our products to wholesalers / distributors including the nationally recognized big Three Major Wholesalers / Distributors, as well as other approved wholesalers / distributors. The number of distributors has not been a significant factor in our ability to estimate returns.

Based on our assessment, we believe this factor is not present and therefore does not impede our ability to make reasonable estimates of product returns.

OXTELLAR XR RETURNS HISTORY

Oxtellar XR was launched in February 2013. The initial lots sold in 2013 had expiration dates ranging from 3Q2015 to 1Q2016. Prior to 3Q2015, as we expected, product return activity was limited. Consequently, prior to 3Q2015, our returns reserve was based primarily on industry experience.

Industry experience demonstrates that lots which are shipped upon launch (i.e., ‘load-in’ lots) typically experience higher rates of return due to product expiry. This occurs because it is difficult to predict, a priori, which pharmacies are likely to experience significant demand for the product and, conversely, which pharmacies will experience little demand. Product returns due to expiry of load-in lots are overwhelmingly driven by returns from ‘slow moving pharmacies’.

SUPN-006

2015 Experience

We, in fact, anticipated that the returns data for load-in lots would be atypically high and reflected this expectation in the return reserve. However, actual returns data for lots expiring in 3Q2015 exceeded our returns estimates. Consequently, we increased our reserve for returns for load-in lots as of mid-2015 to reflect this experience.

Lots shipped subsequent to load in are generally expected to experience substantially lower levels of expiry-driven returns. This occurs primarily because of a self-selection phenomena, whereby only pharmacies that are experiencing demand for product will place a follow on order. Inventory at these pharmacies should be relatively fast moving because there is an underlying base of active patients. Conversely, pharmacies experiencing little/no demand will place few, if any, follow on orders.

Because the return rate for load-in lots exceeded our initial estimates, we also increased our estimates for follow-on lots in 3Q2015, but to a lesser extent.

Throughout this period, we consistently applied our methodology for estimating returns, and accounted for these adjustments as a change in estimate.

2016 Experience

During 2016, we continued to gain additional experience for returns of expired product associated with both the load-in and follow-on lots. The additional experience for the load-in lots was not significantly different than our expectations as of year-end 2015, as we had received [***] of the actual total returns as of December 31, 2015. Consequently, the adjustment in 2016 to the returns reserve for the load-in lots was de minimis.

As of December 31, 2015, we anticipated the returns rates for the follow-on lots would be less than for the load-in lots but greater than the steady-state return rate. However, actual returns data for lots expiring in 2016 exceeded our returns estimates. Therefore, we recognized out of period expense in 2016 as we continued to increase our reserve for returns for these lots, as well as lots expiring in 2017.

During 2016, the Company consistently applied the same methodology in determining our returns allowance. We continued to adjust our reserve to take into account the most recent actual returns information.

In 2016, we recorded a current provision related to sales made in prior periods of [***], as described in our previous comment letter. As mentioned in that letter, this [***] year over year change was comprised of both price and volume adjustments. Of the [***] total, [***] was related to price increases taken during 2016 which affected the returns allowance for sales consummated prior to 2016. The right of return at the new price only

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-007 became effective in 2016; therefore, we do not consider this to be an out-of-period adjustment. The remainder, [***], was attributable to adjustments to the returns reserve to reflect the higher return rates for both load-in and follow-on lots.

The Company concluded that, the [***] adjustment was a refinement in estimate and was accounted for as a change in estimate. Additionally, the Company determined that this amount was not material, either quantitatively or qualitatively, to our overall financial results.

Given that we had actual data from both load-in lots and follow-on lots, and that these data showed that the actual results varied from our estimates by an immaterial amount of [***], the Company continues to conclude we had a strong basis for estimating expected future product returns throughout the year.

SUMMARY AND MATERIALITY ASSESSMENT

During 2016, the Company consistently applied the same methodology in determining our returns allowance. We continued to adjust our reserve to take into account the most recent actual returns experience and information.

In 2016, we recorded a current provision related to sales made in prior periods of [***], as described in our previous comment letter. As mentioned in that letter, this [***] year over year change was comprised of both price and volume adjustments. Of the [***] total, [***] related to price increases taken during 2016 which affected the returns allowance for sales consummated prior to 2016. We do not consider this to be an out-of-period adjustment. The remainder, [***], was attributable to adjustments to the returns reserve for both load-in and follow-on lots.

We considered the materiality of the approximately [***] remaining adjustment (i.e., [***] less the [***] impact of price increase). While we believe that our reported net product sales figure is important to investors, we also believe that the precision of any estimate used in the preparation of financial statements needs to be evaluated in the context of materiality of the overall financial statement preparation. We assessed the materiality and degree of precision of this estimate as compared to the key financial amounts reported in our financial statements. We assessed materiality using quantitative metrics which we actively use in monitoring our business and which we also believe are critical quantitative metrics to investors.

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-008

The impact of this adjustment to the calendar year 2016 is shown in the table below.

Period

($ in Millions)

2016

Impact of Oxtellar XR 2016 recorded current provision related to prior period sales (excluding price increase impact)

$

[***]

As percentage of Balance Sheet Amounts

Total Accrued Sales Deductions

Total Liabilities

As percentage of Income Statement Amounts

Oxtellar XR Net Product Sales

Total Net Product Sales

Total Operating Income

As percentage of Total Gross-to-Net Deductions*

Oxtellar XR Gross Sales

Oxtellar XR Gross-to-Net Deductions

Total Gross Product Sales

Total Gross-to- Deductions

* Note that these amounts are not presented in the financial statements and are included herein for analysis only.

Our analysis, as shown above, shows that the incremental impact of the referenced adjustment is [***] or less in 2016, as measured against reported financial statement amounts. As shown above, the impact of the [***] adjustment is below [***] of total Oxtellar XR net product sales, total net product sales and operating income for 2016. In addition, it represents about [***] of the total gross-to-net deductions for Oxtellar XR and less when compared to total gross-to-net deductions. The impact to other qualitative metrics that both management as well as investors normally use in monitoring progress of our business i.e., current ratio, quick ratio, operating margin, debt service coverage ratio, and debt to equity ratio measures are affected to only a de minimis amount by this change.

*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Supernus Pharmaceuticals, Inc. with respect to portions of this letter.

SUPN-009

Given that we had actual data from both load-in lots and follow-on lots, and that these data showed that the actual results varied from our estimates by an immaterial amount of [***], the Company continues to conclude we had a strong basis for estimating expected future product returns throughout 2016.

Based on discussion above, we believe that Company has a reasonable methodology and strong basis to estimate returns for Oxtellar XR, that the amount of future returns can be reasonably estimated at the time of sale and therefore, continue to believe we can recognize product sales of Oxtellar XR upon product shipment.

Read in the reply
In its next report

First report after the company's reply of Nov 16, 2018: 10-K filed Mar 1, 2019 ↗, against the 10-K filed Mar 1, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2018-12-07

Filing review

2017-08-15 to 2017-10-18 · 4 questions · 2 letters from the SEC, 2 from the company
Review closed 2017-10-18
Results discussion (MD&A)Legal and contingencies
Item 1. Business · In-Licensing Arrangements, page 18
SEC asked (1)
Please revise the descriptions of your agreements with Afecta Pharmaceuticals to quantify any payments to date and disclose the term and termination provisions. Similarly, expand your description of your agreement with Rune Healthcare to explain the meaning of the statement that you obtained a "product concept." Additionally, disclose any payments made to date under the agreement and disclose the term and
Rest of the question

termination provisions.

SUPN answered
As disclosed in our Forms 10-K, we have two license agreements with Afecta Pharmaceuticals, Inc. (“Afecta”) pursuant to which we obtained exclusive worldwide rights to selected product candidates, including an exclusive license to SPN-810. Certain terms of these agreements, particularly those concerning royalty payments and the specified termination date, were redacted when the agreements were filed on March 15, 2012 as Exhibits 10.13 and 10.15 to our Form S-1, and confidential treatment was granted by the SEC in connection with the redacted language therein on April 30, 2012.

We have
Rest of the answer

disclosed in our Forms 10-K for the fiscal years ended December 2012, 2013 and 2014 that we have paid to Afecta an aggregate amount of $550,000 in license fees and milestone payments. No other payments have been made under the agreements because SPN-810 is still in development and we have not developed any other product candidates thereunder.

In addition, we have disclosed in our Forms 10-K for the fiscal years ended December 2012, 2013 and 2014 that we may pay up to $300,000 upon the achievement of certain additional milestones and, if a product candidate is successfully developed and commercialized, we will be obligated to pay royalties to Afecta based on worldwide net product sales at a rate in the low-single digits.

Concerning the term and termination provisions, our Forms 10-K for the fiscal years ended December 2012, 2013 and 2014 disclose that the license agreements will continue in full force and effect on a country-by-country basis until six months from the discontinuation of the commercial sale and collection of revenues for the Afecta product, unless terminated by us or Afecta for material breach or bankruptcy, by Afecta for our discontinuation of development and commercialization activities, or by us for convenience.

Although the license agreements have been publicly filed and there have been no material changes since the historical disclosures, we propose to include these same disclosures in future filings.

Rune

As disclosed in our Forms 10-K, we executed a purchase and sale agreement with Rune HealthCare Limited (“Rune”) where we purchased at closing thereof the exclusive worldwide rights to a product concept from Rune for SPN-809, in consideration of an upfront payment and future royalty payments. More specifically, we acquired the rights to continue the work of Rune to develop a product based on a specific compound for previously undeveloped fields of use, which we have referred to as the “product concept.” The name of the compound and the fields of use were redacted from the definition of the term “product” when the purchase and sale agreement was filed on March 15, 2012 as Exhibit 10.14 to our Form S-1, and confidential treatment was granted by the SEC in connection with the redacted language therein on April 30, 2012. That said, we now propose to state in future filings that, “We have a purchase and sale agreement with Rune HealthCare Limited (Rune) where we obtained from Rune the exclusive worldwide rights to any product developed by us or on our behalf based upon viloxazine or formulations thereof for depression, which includes SPN-809.”

Concerning the disclosure of payments made to date and the term and termination provisions, no payments have been made to date under the agreement other than the up-front fee described below, because SPN-809 is still in development. Moreover, we disclosed in our Forms 10-K for the fiscal years ended December 31, 2012, 2013 and 2014, that we paid Rune a £25,000 up-front fee and, if we receive approval to market and sell any products based on the Rune product concept, we would be obligated to pay royalties to Rune based on net sales worldwide in the low-single digits. We also disclosed that we would be obligated to pay royalties to Rune on a country-by-country basis until the earlier of (a) ten years from the date of first commercial sale of a product based on the Rune product concept, or (b) the market entry in such country of any product utilizing the Rune product by any entity other than us, our affiliates or our licensees, unless terminated by us or Rune for material breach, or by Rune for our discontinuation of development or commercialization activities relating to a product based on the Rune product concept. The specified termination date, however, was redacted when the agreement was filed in March 2012.

Although the Rune Agreement has been publicly filed and there have been no material changes since the historical disclosures, we propose to include these same disclosures in future filings.

Read in the reply
Management’s Discussion and Analysis of Financial Condition and Results of Operations · Overview, page 64
SEC asked (2)
We note that Selling, General & Administrative expenses comprised 66 % of your total costs and expenses for the fiscal year ended December 31, 2016. In future filings, please provide additional information about the components of Selling, General & Administrative expenses, such as quantifying the components and the factors driving the increase from 2015 to 2016 and the extent to which you expect this trend to
Rest of the question

continue. Refer to Item 303(a)(3)(ii) and (iii) of Regulation S-K.

SUPN answered
The Company acknowledges the Staff’s comment regarding providing additional information about the components of Selling, General, and Administrative expenses.

Our selling, general and administrative expenses include costs associated with the commercialization of approved products and general administrative costs to support corporate functions.
Rest of the answer

Selling and marketing expenses primarily consist of: compensation and benefits for our sales force; compensation and benefits for personnel whose primary function is to support our sales force; compensation and benefits for marketing personnel; and external marketing and medical affairs program costs. General and administrative expenses include compensation and benefits associated with our general corporate functions such as: information technology; regulatory affairs; executive management; finance/accounting, legal, and human resource management; and external costs such as insurance, facilities costs, and professional service fees.

The Company proposes modifying its disclosure in the MD&A section of future filings as described below, and will include quantification of the components and factors driving period to period changes.

Years Ended December 31

Increase

(In thousands)

2016

2015

2016 vs 2015

Selling and marketing

$

79,089

69,095

9,994

General and administrative

26,921

19,968

6,953

Total selling, general and administrative expenses

106,010

89,063

16,947

Selling and marketing. The increase in selling and marketing expenses of approximately $10.0 million for the year ended December 31, 2016, as compared to the same period in 2015, is primarily the result of an increase in workforce headcount and infrastructure support for our commercial products, coupled with development and production of promotional materials and marketing programs in preparation for the launch of the migraine indication for Trokendi XR in 2017. Of this total, approximately $4.2 million is due to increased compensation, benefits and other employee-related expenses associated with increased headcount in our field sales force; approximately $3.0 million is due to increased expenses for marketing programs, speaker programs, and consulting services in anticipation of launching the migraine indication for Trokendi

XR in 2017; and approximately $1.6 million is due to increased spending for medical affairs programs to support our commercial products.

As we continue to invest in the commercialization of Trokendi XR and Oxtellar XR, we expect our selling and marketing expenses to continue to increase for the foreseeable future. We expense all selling and marketing costs as incurred.

General and administrative. The increase in general and administrative expenses of $7.0 million for the year ended December 31, 2016, as compared to the same period in 2015, primarily resulted from: $2.8 million in higher accounting and professional fees related to the first year of SOX 404 testing and attestation, coupled with costs to restate our 2014, 2015, and 2016 financial statements; $1.3 million in increased patent amortization expense; $0.9 million in increased information technology expenses; and $0.6 million in increased executive compensation.

We expect our general and administrative expenses to continue to increase for the foreseeable future, as we continue to invest in areas such as compliance, finance, management of our intellectual property portfolio, information technology systems and personnel, in each case commensurate with the growth of our business. We expense all general and administrative costs as incurred.

Read in the reply
Financial Statements · Note 6. Deferred Legal Fees and Intangible Assets, page 98
SEC asked (3)
Please provide us an analysis with reference to authoritative literature supporting your accounting policies: • for recording legal fees incurred in connection with legal proceedings related to the defense of patents for Oxtellar XR and Trokendi XR as an asset before the litigation is resolved.; and • for delaying the amortization of those deferred legal fees until a successful outcome of the litigation. .
SUPN answered
The Company acknowledges the Staff’s comment regarding capitalizing deferred legal fees and intangible assets.

The Company recognizes that there is diversity of practice as regards the treatment of external legal fees incurred in connection with the defense of patents. Specifically, these costs can be deferred if it is probable that patent validity will ultimately be substantiated; that incurring such costs enables the Company to realize future economic value from the patent(s); and that upon successfully defending the patent, these deferred costs can then be capitalized as an intangible
Rest of the answer

asset. An alternative treatment when accounting for patent defense costs allows for expensing costs as incurred. In practice, capitalizing or expensing external patent defense costs is an accounting policy decision.

The Company believes that the decision of whether to capitalize or expense costs associated with the defense of its patents is an accounting policy decision that should take into account the prospective increase in economic benefits consequent to a successful patent defense, and that a successful patent defense in the cases specific to the Company was assessed to be probable. Based on this assessment, the Company elected to follow the former approach; i.e., to capitalize costs, based on the authoritative literature summarized below.

Authoritative Literature Citations

The Company has elected to capitalize external patent defense costs. That decision is supported by the authoritative literature summarized below.

· AICPA Technical Practice Aid, Technical Questions and Answers Section 2260:

States that “If defense of the patent lawsuit is successful, costs may be capitalized to the extent of an evident increase in the value of the patent. Legal costs which relate to an unsuccessful outcome should be expensed.”

· Statement of Financial Accounting Concepts No. 6, paragraph 247:

States that “. . . the legal and other costs of successfully defending a patent from infringement are “deferred legal costs” only in the sense that they are part of the cost of retaining and obtaining the future economic benefit of the patent.”

· Statement of Financial Accounting Concepts No. 6, paragraph 25:

States that “Assets are probable future economic benefits obtained or controlled by a particular entity as a result of past transactions or events.”

The Company believes that the decision to capitalize or expense costs associated with the defense of its patents is an accounting policy decision. Such a decision takes into account the prospective increase in economic benefits consequent to a successful legal defense, or in reaching a negotiated settlement with generic filers. In the specific cases of our commercial products, Trokendi XR and Oxtellar XR, the Company assessed that successful patent defense was highly probable.

Situation Analysis

With regard to the defense of the patents for Oxtellar XR and Trokendi XR, the Company concluded at the outset of the various litigations that a successful defense was highly probable. That judgment was based on two sets of facts. First, that the formulations for Oxtellar XR and Trokendi XR are novel extended release formulations, utilizing the Company’s unique and proprietary extended release and bio-availability technologies. The Company assessed that it was highly probable that, once the patents for each product were issued, generic manufacturers would find it very difficult to develop bio-equivalent formulations of Oxtellar XR and Trokendi XR without infringing on the Company’s issued patents.

Second, after the initial patent filings for Oxtellar XR and Trokendi XR, the Company continued to build upon the patent position of each product. By erecting additional barriers to generic entry, the Company further increased the probability of successful patent defense. As of the date of this letter, the Company has built the patent protection on Oxtellar XR with a total of seven (7) issued patents and on Trokendi XR with a total of nine (9) issued patents. All of these patents are listed in the FDA’s Orange Book.

Once a generic manufacturer notifies the originator of its intent to launch a generic equivalent, and assuming that the originator responds by initiating legal action to protect its patent position, by law the FDA is enjoined from approving the generic product for a 30 month period. During this period, the courts endeavor to bring the patent litigation to resolution. In the event of an unsuccessful defense, generic competition can commence as early as the end of this 30 month period. Once commenced, generic competition rapidly reduces the ongoing economic value of the originator’s product, due to erosion of both price and unit volume.

By successfully defending its patents, the onset of generic competition can be delayed well beyond the initial 30 month period, thereby significantly enhancing the economic value of the underlying product. Successful patent defense is evidenced by either a favorable verdict at trial, or a negotiated settlement between the original manufacturer and the generic infringer(s). Either outcome can create significant economic gain for the original manufacturer due to the incremental profit earned after the 30 month period. This increase in value can be directly attributed to the success of the patent defense efforts.

Subsequent Legal Proceedings

Events subsequent to our original assessment of the likely outcome of patent litigation have corroborated our assessment of the strength and durability of our patent position. In early 2016, a court ruled in our lawsuit against Actavis, Inc. et al, that our first three Oxtellar XR patents, which were the subject of the trial, were valid and that the Actavis formulation was ruled to infringe two of those three patents. This judgment was upheld upon appeal. In May 2017, a court ruled in our lawsuit against TWi Pharmaceuticals et al, that our Oxtellar XR patents are valid and that TWi infringed multiple Oxtellar XR patents. Generic entry is now expected to occur no earlier than 2027.

With regard to Trokendi XR, we have entered into settlement agreements with various generic filers, whereby they acknowledged the validity of our patents. We believe that the agreements reached with these generic filers will result in generic entry in January 2023.

Enhancing Value of Patents

The Company launched Oxtellar XR and Trokendi XR in 2013 and received its first Paragraph IV notification, (i.e., notification from a generic infringer), in July of 2013. Failure to defend our patents could have resulted in generic competition for our products as early as 30 months after the initial filing. Because generic manufacturers generally price their product offerings at an 80% to 90% discount to the branded product, generic competition rapidly erodes the revenue base of the branded product. This erosion is substantially complete within twelve (12) months after generic entry into the market.

The economic consequences of failing to uphold our patent position are dramatic. Using equity analyst forecasts as a basis for estimation, generic entry in 2016, as compared to generic entry at the end of the patent life of Oxtellar XR in 2027, would result in an estimated cumulative loss of $0.5B in gross profit. As regards Trokendi XR, and once again using equity analyst forecasts as a basis for estimation, generic competition in 2018 would result in an estimated cumulative loss of $1.5B in gross profit, as compared to the now anticipated generic entry date of January 2023.

With respect to each product, the financial return on investment in external patent defense expenditures has been very favorable, given that the incremental impact as measured by prospective loss of product gross profit dramatically exceeds the patent defense expenditures.

Amortization of Capitalized Costs

Consistent with guidance in both AICPA Technical Practice Aid, Section 2260, as well as Statement of Financial Accounting Concepts No. 6, the Company recorded legal fees incurred in connection with the defense of patents for Oxtellar XR and Trokendi XR as “Deferred Legal Fees.” In doing so, the Company explicitly recognized that the external legal costs of defending the patents from generic drug makers would create future economic benefits, with the proviso that those efforts would be successful. Such benefits are evidenced in additional cash flows, as discussed above, and are the direct result of extending the economic life of the patent beyond 30 months.

As described above, upon successful outcome of patent litigation, from either a court ruling or a negotiated settlement, these costs were reclassified from “Deferred Legal Fees” and recorded as capitalized patent defense costs, as a component of “Intangible Assets.” Coincident with capitalizing deferred external legal defense costs, the Company commenced amortization of the intangible asset. The Company believes that patent defense costs were placed into service or ready for their intended use only after the litigation was successfully resolved, and the patents defended from attack by the generic infringers. The legal defense costs clearly relate to the period beyond the initial 30 month period, because prior to that point in time, the patents were protected by the legally stipulated 30 month ‘stay period.’ However, after the 30 month ‘stay period’ expired, only the success of the external legal efforts protects the revenue stream from generic competition. In this sense, the deferred legal costs were ‘placed in service’ only at this point in time.

Moreover, commencing amortization of the intangible asset after successful resolution of litigation matches the recognition of the cost of the asset with the timeframe over which future cash flows are realized. Additionally, we note that prior to resolution of litigation, the total legal cost incurred to defend the patent and the term of the useful life cannot be reliably determined. Subsequent to resolution of litigation, the useful life of the intangible asset is based on the timing of expected generic competition.

As described above, the Company believes that the triggering event in determining the commencement of amortization is the successful resolution of litigation, because it is at this time that the intangible asset is created and put in service. In that regard, the accounting literature is replete with examples wherein assets are amortized only after those assets are ready for their intended use. Specifically, as noted in the following accounting literature:

· FASB Accounting Standards Codification (ASC) 360-10-35-4 defines depreciation accounting as “a system of accounting which aims to distribute the cost or other basic value of tangible capital assets, less salvage (if any), over the estimated useful life of the unit (which may be a group of assets) in a systematic and rational manner.”

· ASC 835-20-25-5 and ASC 350-40-25-14 which states that capitalization should end and depreciation should begin when the asset is substantially complete and ready for its intended use.

· ASC 350-30-35-1 to 35-2 states that: “The accounting for a recognized intangible asset is based on its useful life to the reporting entity. An intangible asset with a finite useful life shall be amortized; an intangible asset with an indefinite useful life shall not be amortized. The useful life of an intangible asset to an entity is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of that entity.”

· ASC Master Glossary states that: “Intended use of an asset embraces both readiness for use and readiness for sale, depending on the purpose of acquisition.”

As discussed previously herein, external legal fees were incurred to defend the patents from generic infringers. Only upon successful resolution of the litigation is the asset considered to be ready and placed in service for the specific intended use. Moreover, depreciation accounting is a process of allocation that is intended to allocate an asset’s cost as equitably as possible to the periods during which the Company benefits from the use of the asset. We believe that for the capitalized patent defense cost, this is the period beyond the initial 30 months.

Our accounting for deferred legal fees and capitalized patent defense cost is likewise analogous to accounting of property, plant and equipment under ASC 360-10-30-1, which states that the historical cost of acquiring an asset includes the costs necessarily incurred to bring it to the condition and location necessary for its intended use.

To summarize, amortization of the capitalized patent costs did not commence until either a favorable court ruling or settlement. The Company believes that the triggering event in determining the commencement of amortization of the asset is the resolution of the litigation because it is at this time, with the uncertainty of litigation removed, that additional value may be realized from the asset in the form of future cash flows. Moreover, commencing amortization of the intangible asset upon resolution of the litigation matches the recognition of the cost of the asset with the future cash flows.

The Company therefore believes that its practice is appropriate; i.e., to defer legal expenses associated with patent defense costs when we believe a successful outcome is not only probable but also enhances the value of the patent; to capitalize these costs as an intangible asset upon a successful outcome of the litigation; and to begin amortizing this intangible asset at the time of capitalization.

Updated Disclosure

The Company proposes to add the following disclosure to its Accounting Policy footnote to its consolidated financial statements in future filings.

“The Company defers legal fees related to the defense of patents when it believes a successful defense of that patent is probable, and that the successful defense increases the value of the patent.”

Read in the reply
Financial Statements · Note 6. Deferred Legal Fees and Intangible Assets, page 98
SEC asked
With regard to your response to comment 3 you note that FASB Concept No. 6, Elements of Financial Statements—a replacement of FASB Concepts Statement No. 3 (incorporating an amendment of FASB Concepts Statement No. 2), (CON6), paragraph 247 states ". . .
Rest of the question

the legal and other costs of successfully defending a patent from infringement are 'deferred legal costs' only in the sense that they are part of the cost of retaining and obtaining the future economic benefit of the patent." We also refer you to paragraph 248 of CON6 which states “The examples in the preceding paragraph illustrate costs that are accounted for in current practice as costs of other assets rather than as assets by themselves.” As the deferred legal fees are not a separate asset and you are using the related patent asset, we believe amortization of the deferred legal fees should begin upon capitalization. Also, we believe deferred legal fees should be classified as part of intangible assets on the balance sheet as they are part of the patent cost. Please revise your financial statements as necessary or tell us why no revision is required.

SUPN answered
This letter serves as the further response of Supernus Pharmaceuticals, Inc. (the “Company,” “we” or “our”) pursuant to our telephone discussion with and the comment letter received from the Staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission on September 20, 2017.
Rest of the answer

This letter also serves to confirm that the responses in our letter dated August 29, 2017 to comments 1 and 2 of the Staff’s letter dated August 15, 2017 are satisfactory to the Staff and that no further action is required by the Company except as set forth in our responses therein.

Concerning comment 3, the Company acknowledges the Staff’s comment that deferred legal fees are related to the underlying patent asset, and that amortization of deferred legal fees should begin upon capitalization.

Accordingly, the Company has analyzed the impact of this change, from 2013 forward. Initially, we used the life of the patent to establish the appropriate amortization period. That amortization period was subsequently adjusted, on a go forward basis, to impound changes to the effective economic life of the patent, consistent with the Company’s judicial findings and finalized settlement agreements with generic filers for Trokendi XR and Oxtellar XR. The results of our analysis, calculated on a quarterly and annual basis, are shown in Attachment I.

Materiality Assessment

The Company assessed the financial statement impact of the error correction, as described above, using both quantitative and qualitative factors. The Company has concluded that analysis on both quantitative and qualitative bases supports the conclusion that the correction of the error is not material to the Company’s reported financial results, from 2013 through 2017.

Quantitative Factors

We assessed materiality (see Attachment I) on a quarterly and annual basis, using quantitative metrics which we actively use in monitoring our business and which we also believe are critical quantitative metrics to investors. Because materiality is most appropriately assessed on an annual basis, the impact of this correction of an error is shown in the table below on a calendar year basis.

Period

( $ Thousands )

2013

2014

2015

2016

2017 (Q1+Q2)

Impact of Correction

174

808

1,487

658

As Percent of Revenue

0.0

%

0.2

0.5

0.7

As Percent of SG&A Expense

0.9

1.4

0.8

As Percent of Operating Income

-3.3

3.9

2.7

1.5

Our analysis, as shown above, shows that the incremental impact of effectuating the referenced correction of an error is below 5% in each of the last four (4) years and the two (2) most recent quarters, as measured against reported revenue, selling, general and administrative (SG&A) expense, and operating income. Furthermore, our quantitative analysis of materiality, which includes assessing both the annual and cumulative impact of the error correction in each period; i.e., the rollover and iron curtain approaches, respectively, shows the impact on both prior and current periods is below 5% of operating income.

Based on our forecasts for calendar year 2017, we believe that correction of this error is immaterial to the Company’s financial results, as set forth in the table below:

2017

Cumulative through

December 31, 2016

June 30, 2017

2,475

3,133

1.1

1.7

2.2

2.9

3.7

Recording the out-of-period amortization expense during 2017, as shown above, would result in an impact below 5% of revenue, SG&A expense and operating income for 2017.

Based on the quantitative analysis described herein, we believe that the correction of the error would not materially affect our prior reported financial results. Accordingly, it is not necessary to amend the Company’s prior financial filings. Further, we believe that the impact of recording a catch-up adjustment in 2017 is quantitatively immaterial and would not materially misstate the current period financial statements.

Qualitative Factors

In a like fashion, the Company assessed the materiality of the correction of the error on a qualitative basis. The most important qualitative considerations of this error correction are the impact on the Company’s cash position, as well as potential impact on its historical statements of cash flows. Because this correction of error results in an increase in non-cash expense, it would affect neither the Company’s cash position nor its historical statements of cash flow. We believe the non-cash nature of this error correction suggests it is immaterial to investors and the Company.

In addition to the above considerations, the Company evaluated the impact of the error correction on the qualitative metrics that both management as well as investors normally use in monitoring progress of our business. The current ratio, quick ratio, and debt service coverage ratio are unaffected by this change. The operating margin and debt to equity ratio measures are affected to only a de minimus amount by this change. We further analyzed the impact of this change and determined that the misstatement does not in any period change a loss into income or vice versa nor does it mask a change in the earnings trends.

Therefore, the Company concluded that, on a qualitative basis, the correction of the error does not materially affect the Company’s financial results.

Proposed Disclosure: Report on Form 10-Q for period ended September 30, 2017 and on Form 10-K for period ended December 31, 2017

The Company proposes including the following disclosure on Form 10-Q, for the period ended September 30, 2017. Accordingly, the disclosures below will be made on the Form 10-K for the period ended December 31, 2017, as well.

Balance Sheet Presentation

We recognize the Staff’s comment regarding the classification of deferred legal fees within intangible assets on the balance sheet. We will ensure this reclassification occurs in all future filings.

Accounting Policy Disclosures

The Company proposes to update the Footnote 2 Disclosure for Intangible Assets as follows:

Footnote 2 — Intangible Assets

Intangible Assets consist of patent defense costs; i.e., deferred legal fees that have been incurred in connection with legal proceedings related to the defense of patents for Oxtellar XR and Trokendi XR. Patent defense costs will be charged to expense in the event of an unsuccessful outcome of the ongoing litigation. Patents are carried at cost less accumulated amortization, which is calculated on a straight-line basis over the estimated useful lives of the patents. The carrying value of the patents are assessed for impairment annually during the fourth quarter of each year, or more frequently if impairment indicators exist. There were no indicators of impairment identified at December 31, 2016.

The Company proposes to update the Footnote 6 Disclosure for Intangible Assets as follows:

Footnote 6 - Intangible Assets

Intangible assets consist of patent defense costs; i.e., deferred legal fees incurred in conjunction with defending patents for Oxtellar XR and Trokendi XR.

The following sets forth the gross carrying amount and related accumulated amortization of the intangible asset, in thousands:

Weighted-

September 30,

December 31,

Average Life

Capitalized patent defense costs

5.9 - 11 years

$

XXX

37,663

Less accumulated amortization

(XXX

)

(3,758

33,875

In March 2017, the Company entered into two settlements with various companies related to Trokendi XR patent litigation. Following the settlements, the Company began amortizing the remaining unamortized capitalized patent defense cost for Trokendi XR through the settlement date of January 1, 2023.

The net book value of intangible assets was $XX.X million as of September 30, 2017 and $33.9 million as of December 31, 2016.

Amortization expense related to intangible assets was approximately $XX million and $3.8 million for the period ended September 30, 2017 and December 31, 2016, respectively.

There were no indicators of impairment identified.

The Company proposes to update the MD&A Disclosure for the Deferred Legal Fees section under the Critical Accounting Policies and Use of Estimates as follows:

Intangible Assets

Intangible assets consist of patent defense costs; i.e., deferred legal fees that have been incurred in connection with legal proceedings related to the defense of patents for Oxtellar XR and Trokendi XR. Amortization commences in the quarter after the costs are incurred. This amortization period is based initially upon the remaining patent life and is adjusted, if necessary, for any settlements or other changes to the expected useful life of the patent. Patent defense costs will be charged to expense in the event of an unsuccessful outcome of the on-going litigation.

Internal control over financial reporting considerations

The Company would like to note that its internal controls and processes are under continuous consideration to keep up with changing conditions and business environment.

This correction of an error did not result in a change in our control environment.

Read in the reply

Also in this review: closing letter, 2017-10-18

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Aug 7, 2019 · SEC: review completed · Constellation Alpha Capital Corp. · Form 10-K for the Fiscal Year ended March 31, 2019...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 13 letters filed since 2017-08-15. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SUPN/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.